Research Activities
In-vivo Pharmacology
Our research in in-vivo pharmacology is focused on inflammation and various endocrine and metabolic diseases. Our strategies include
- Discovery and development of gastrointestinal and cardiovascular safe anti-inflammatory drugs based on nitric oxide-donating technology
- Discovering potent non-PPARg insulin sensitizers, which are devoid of adverse effects, associated with currently available PPARg agonists
- Identifying novel targets and mechanisms to treat post-prandial hyperglycemia
- Screening of compounds from a diverse chemical and natural products (herbal and marine) library to identify promising leads that are effective in treating metabolic diseases
- In-vivo profiling of new chemical entities showing promising activity forefficacy, safety and toxicity
Several animal models available in house:
- Carrageenan-induced inflammation and hyperalgesia
- Freud's adjuvant-induced arthritis in rats
- L-NAME-induced hypertension in rats
- STZ-induced Type 1 diabetes model in wistar rats
- db/db (Leprdb), a genetic mice model for Type 2 diabetes
- High fat diet + low dose STZ model of Type 2 diabetes in rats
- Insulin resistance model for Type 2 diabetes
- Hypertriglyceridemia and associated metabolic syndrome in rats
- Triton-induced hyperlipidamia model
- High fat diet induced obesity model in C57BL/6J mice
Our strengths
- State of art central animal house facility with individual ventilated cage system
- Expertise in pharmacokinetic studies
- Invasive and non-invasive blood pressure measurement
- Ex-vivo and in vitro glucose uptake studies
- Oral and paraentral glucose tolerance tests
- Complete serum biochemical profiling
- ELISA-based quantification
- Acute, sub acute, as well as 28-day repeat dose toxicity studies.